- Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
- Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
- Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
- Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Key statistics
On Wednesday, Boundless Bio Inc (BOLD:NSQ) closed at 11.02, 29.49% above the 52 week low of 8.51 set on May 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.65 |
---|---|
High | 11.33 |
Low | 10.65 |
Bid | 5.00 |
Offer | 11.61 |
Previous close | 10.99 |
Average volume | 92.96k |
---|---|
Shares outstanding | 22.25m |
Free float | 19.70m |
P/E (TTM) | -- |
Market cap | 244.58m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼